Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | HTR6 | P50406 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | AGXT | P21549 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27718613 | 0.98 | HTR7 (0.61) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL15244883 | 0.93 | TAAR1 (0.63) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL29706557 | 0.88 | MAOA (0.57) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL4035870 | 0.88 | MAOA (0.57) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL3229152 | 0.86 | MAOA (0.55) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| SCHEMBL21540883 | 0.84 | PRKCI (0.62) | TAAR1LOXL2HTR7HTR6HTR2C | |
| SCHEMBL18070223 | 0.84 | TAAR1 (0.69) | TAAR1HTR7HTR2CAGXTMAOB | |
| SCHEMBL609715 | 0.84 | MAOA (0.53) | TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2 | |
| Hydrochloric Acid SCHEMBL5366344 | 0.83 | TAAR1 (0.61) | TAAR1HTR2AHTR7HTR6HTR2C | |
| SCHEMBL29400616 | 0.82 | TAAR1 (0.70) | TAAR1LOXL2AGXTAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023202582-A1 | GPCR REGULATOR AND USE THEREOF | 北京昌平实验室 | 2023-10-26 | — | — | WO | disclosed |
| WO-2023149945-A1 | PEPTIDOMIMETIC INHIBITORS OF PROTEIN N-TERMINAL METHYLTRANSFERASE 1, COMPOSITION, AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2015089137-A1 | ACYLGUANIDINES AS TRYPTOPHAN HYDROXYLASE INHIBITORS | KAROS PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-1768966-B1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110212080-A1 | UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7851637-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851637-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-1732929-B1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | HANASAKI KOJI (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6818640-B1 | BIND SELECTIVELY TO CANNABINOID 2 RECEPTOR; ANTIINFLAMMATORY AGENTS | SHIONOGI & CO., LTD. (JP) | 2004-11-16 | — | — | US | disclosed |
| CN-1514831-A | Medicinal composition containing 1,3-thiazine derivative | ��Ұ����ҩ��ʽ���� | 2004-07-21 | — | — | CN | disclosed |
| US-20040116326-A1 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1375489-A1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| CN-1387519-A | 2-imino-1, 3-thiazine derivatives | SHIONOGI & CO (JP) | 2002-12-25 | — | — | CN | disclosed |
| EP-1219612-A1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6090852-A | MATRIX METALLOPROTEASE INHIBITOR | PFIZER INC (US) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | TAAR1 173/4885HTR2A 206/4885CYP2A6 1120/4885 |
| US-20110212080-A1 | UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | SLC14A1, LPXN, UBXN1 | TAAR1 4130/4885HTR2A 4804/4885CYP2A6 3355/4885 |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | CNR2, CNR1, HTR2C | TAAR1 99/4885HTR2A 8/4885CYP2A6 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.